E-Posters-10061

10061_Gonzalez

Pdf Summary

This study sought to determine whether symptom severity predicts the response rate to Onabotulinum A toxin for the treatment of urge urinary incontinence (UUI). The study included 28 patients, with 11 classified as having mild symptoms and 17 classified as having severe symptoms. The results showed no difference in success between the two groups, with both groups experiencing a mean time to retreatment of 11 months. Both groups also showed significant improvement in UUI, UDI-6, and IIQ-7 scores from baseline to 4 weeks. The median change in UUI was -4 for the mild group and -15 for the severe group. At 6 months, both groups showed persistent improvement from baseline in UDI-6 and IIQ-7 scores. However, analysis at 6 and 12 months regarding UUI episodes could not be conducted due to loss to follow-up and patient non-compliance with the 3-day voiding diary. <br /><br />The study concluded that 50 units of Onabotulinum A toxin is an effective dose for the treatment of mild/moderate and severe UUI. There was a satisfactory response regardless of symptom severity, and the time to retreatment was similar in both groups. The results suggest that the risk of self-catheterization may be lower with 50 units. Therefore, Onabotulinum A toxin can be considered as a second-line treatment option even for patients with milder symptoms. However, it's important to note that the views expressed in this study are those of the authors and do not necessarily reflect the official policy or position of the Department of the Navy, Air Force, Department of Defense, or the US Government. The study highlights the need for further research on the dose-dependent response to Onabotulinum A toxin and its effectiveness in different symptom severity groups.

Keywords

symptom severity

Onabotulinum A toxin

urge urinary incontinence

response rate

treatment

mild symptoms

severe symptoms

time to retreatment

improvement

research